Dec 16, 2016 9:27am EST Recro Pharma Announces Closing of $40 Million Public Offering of Common Stock
Nov 28, 2016 7:00am EST Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam